Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
NIS793 - TGFẞ1 inhibitor
Appendix
References
Innovation: Clinical trials
Abbreviations
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milestone(s)
Publication
NCT04935359 (CNIS793B12301)
1L metastatic pancreatic ductal adenocarcinoma
Phase 3
490
Safety run-in part: Percentage of participants with dose limiting toxicities (DLTs)
during the first cycle (4 weeks) of treatment
Randomized part: Overall survival (OS)
Randomized portion of the study:
Arm 1: NIS793+gemcitabine+nab-paclitaxel
Arm 2: placebo+gemcitabine+nab-paclitaxel
Patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), first line
treatment
Primary 2025
TBD
92 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation